Physician profile
Paul Berkowitz
NPI 1275564197
$2,262.79
in general payments reported to CMS, 2019-2025
18 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $700 · 2023: $487 · 2024: $516 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,081.12 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $481.93 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $124.56 | 2023-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $95.09 | 2024-2025 | Auvelity |
| Abbvie INC. | $82.63 | 2023-2024 | Vraylar |
| Lundbeck LLC | $56.99 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.45 | 2023-2024 | Caplyta |
| Tris Pharma INC | $39.24 | 2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $37.63 | 2023-2025 | Trintellix |
| Alkermes, INC. | $37.14 | 2023-2024 | Aristada, Lybalvi |
| Corium, LLC | $36.81 | 2024-2025 | Azstarys |
| Bausch Health US, LLC | $22.29 | 2024 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $21.14 | 2023 | Adzenys Xr-Odt |
| Owp Pharmaceuticals, INC. | $21.10 | 2024 | Subvenite |
| Almatica Pharma LLC | $19.86 | 2023 | Loreev Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $18.45 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $16.79 | 2025 | Relexxii |
| Ironshore Pharmaceuticals INC. | $13.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.